Osteoporosis in Chronic Hepatitis C
نویسندگان
چکیده
منابع مشابه
Hepatitis C Virus Genotyping in Chronic Hepatitis C Patients
Chronic hepatitis C virus infection is a massive worldwide healthcare burden with estimated costs in the USA alone of over $5 billon per annum. The virus has a 9.5kb positive sense single-stranded RNA genome with striking heterogeneity between isolates, which has led to it being divided into 6 genotypes and more than 50 subtypes and many quasispecies that has been arisen due to the infidelity o...
متن کاملChronic Hepatitis C
The goal of antiviral therapy for patients with chronic hepatitis C virus (HCV) infection is to attain a sustained virologic response (SVR), which is defined as undetectable serum HCV-RNA levels at 6 months after the cessation of treatment. Major improvements in antiviral therapy for chronic hepatitis C have occurred in the past decade. The addition of ribavirin to interferon-alfa therapy and t...
متن کاملSero-Epidemiology of Hepatitis E Infections in patients with chronic Hepatitis C virus infection in Jahrom, Southern Iran
Background and Aims: Co-infection of hepatitis E virus (HEV) in chronic hepatitis C virus (HCV) infected patients can develop and increase liver disease and hepatic complications in the world. The purpose of this study was to assess the prevalence of HEV infection in patients suffering from chronic HCV infection. Materials and Methods: Cross-sectional study testing anti-HEV antibodies in serum...
متن کاملHistorical treatment of chronic hepatitis B and chronic hepatitis C.
Interferon is currently considered to be the only accepted effective treatment for chronic viral hepatitis. A history of the treatment of chronic hepatitis B and C before the use of interferon is presented here. Hepatitis B virus does not seem to be directly cytopathic and the disease is known to be modulated largely by the host's immune response. Experience with immunosuppressant and immunosti...
متن کاملRosuvastatin and chronic hepatitis C
The prospective randomized clinical trial of Malaguarnera and colleagues, published in the current issue of Hepatitis Monthly, investigates the potential role of a commercially available HMG Co-A reductase agent—rosuvastatin (Crestor, Astra Zeneca)—in combination with non-pegylated interferon and ribavirin in the treatment of chronic hepatitis C (HCV). HMG Co-A reductase agents, commonly referr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Afro-Egyptian Journal of Infectious and Endemic Diseases
سال: 2014
ISSN: 2090-7184
DOI: 10.21608/aeji.2014.17189